Teva Pharma (TEVA) Tops Q2 EPS by 12c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Teva Reports Second Quarter 2022 Financial Results
July 26, 2022 4:55 PM EDTTeva has reached agreement in principle on the primary financial terms of a nationwide opioids settlement and has revised its provision to reflect its terms
Key financial highlights and outlook
Revenues of $3.8 billion GAAP diluted loss per share of $0.21 Non-GAAP diluted EPS of $0.68 Cash flow generated from operating activities of $123 million Free cash flow of $301 million 2022 revenues outlook revised mainly due to continued foreign exchange headwinds; COPAXONE® outlook revised lower mainly to reflect increased competition and foreign exchange... More